Lucira Health (NASDAQ:LHDXQ – Get Rating) is one of 40 public companies in the "Diagnostic substances" industry, but how does it compare to its competitors? We will compare Lucira Health to related businesses based on the strength of its profitability, analyst recommendations, institutional ownership, earnings, valuation, dividends and risk.
Profitability
This table compares Lucira Health and its competitors' net margins, return on equity and return on assets.
Get Lucira Health alerts:| Net Margins | Return on Equity | Return on Assets | |
| Lucira Health | -67.54% | -13.55% | -8.47% |
| Lucira Health Competitors | -802.63% | -114.55% | -27.76% |
Institutional and Insider Ownership
57.0% of Lucira Health shares are owned by institutional investors. Comparatively, 48.2% of shares of all "Diagnostic substances" companies are owned by institutional investors. 30.4% of Lucira Health shares are owned by insiders. Comparatively, 12.9% of shares of all "Diagnostic substances" companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Lucira Health and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lucira Health | 0 | 0 | 0 | 0 | N/A |
| Lucira Health Competitors | 371 | 632 | 1236 | 19 | 2.40 |
As a group, "Diagnostic substances" companies have a potential upside of 36.92%. Given Lucira Health's competitors higher probable upside, analysts clearly believe Lucira Health has less favorable growth aspects than its competitors.
Volatility & Risk
Lucira Health has a beta of 3.36, indicating that its share price is 236% more volatile than the S&P 500. Comparatively, Lucira Health's competitors have a beta of 1.36, indicating that their average share price is 36% more volatile than the S&P 500.
Valuation and Earnings
This table compares Lucira Health and its competitors revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Lucira Health | $93.06 million | -$64.83 million | -0.01 |
| Lucira Health Competitors | $480.44 million | $10.80 million | -55.18 |
Lucira Health's competitors have higher revenue and earnings than Lucira Health. Lucira Health is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Summary
Lucira Health beats its competitors on 7 of the 10 factors compared.
About Lucira Health
(Get Rating)
Lucira Health Inc. is a medical technology company. It is focused on the development and commercialization of transformative and infectious disease test kits. Lucira Health Inc. is based in Emeryville, California.
Receive News & Ratings for Lucira Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucira Health and related companies with MarketBeat.com's FREE daily email newsletter.